Shares of OncoMed Pharmaceuticals Inc. OMED closed the day down 3.74% to $3.86 per share. The plunge came after both JMP JMP and Piper Jaffray PJC downgraded the company’s rating. Both firms gave the same reason for the cut: …
OMED closed Monday's trading at $3.77, up 1.07%. In after-hours, the stock was down 1.33% to $3.72. The FDA has approved Sanofi's (SNY) Thymoglobulin for use in conjunction with concomitant immunosuppression in the prophylaxis, …
OMED) saw its shares crumble after the company announced that Bayer Pharma is terminating its option agreement with the company, as well as a missed mid-stage trial. After having a relatively positive year thus far, this is a huge setback …
ABIO stock jumped over 43%, while OMED stock and IMMU stock each gained just under 8%. Finally, MACK stock tacked on nearly 7%. Of the biggest movers in the world of pharma-related small caps stocks, only OMED stock, …
OncoMed Pharmaceuticals Inc. (OMED) announced Monday morning that its Phase 2 trial ... OncoMed gapped open sharply lower Monday and has continued to weaken in early trade. The stock is now down 3.43 at $5.33 with volume at …
A year ago, they were trading at $3.69. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OMED at https://www.zacks.com/ap/OMED
OncoMed Pharma (NASDAQ: OMED) announced that it has completed patient enrollment in its Phase 2 "ALPINE" clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) for the treatment of pancreatic cancer more than eight months ahead of …
OncoMed Pharmaceuticals, Inc. (OMED) saw a big move last session, as the company’s shares fell by about 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This …
OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) saw its stock sink early Monday morning following an update from its Phase 2 Alpine study. The company announced an update following a pre-planned January 23 interim efficacy …